keyword
MENU ▼
Read by QxMD icon Read
search

Breast carcinoma in situ

keyword
https://www.readbyqxmd.com/read/28651115/ten-year-results-of-applying-an-original-scoring-system-for-addressing-adjuvant-therapy-use-after-breast-conserving-surgery-for-ductal-carcinoma-in-situ-of-the-breast
#1
Massimiliano Gennaro, Maria Carmen De Santis, Luigi Mariani, Salvatore Lo Vullo, Vera Cappelletti, Roberto Agresti, Umberto Cortinovis, Biagio Paolini, Serena Di Cosimo, Maria Luisa Carcangiu, Maria Grazia Daidone, Laura Lozza
PURPOSE: Although large-scale randomised clinical trials have established that radiotherapy (RT) - alone or combined with hormonal therapy (HT) - is effective in reducing the risk of ipsilateral breast tumour recurrence (IBTR), overall survival does not seem to be improved by adjuvant therapies. We sought to ascertain whether specific criteria can be adopted to avoid RT with an acceptable rate of IBTR after breast-conserving surgery (BCS) achieving tumour-free margins. PATIENTS AND METHODS: This non-randomised prospective study concerned the outcome of patients who underwent BCS for ductal carcinoma in situ (DCIS) and were prospectively assessed by means of an established scoring system based on width of free margins in association with age <40, presence of comedonecrosis, high grade, ER negativity and HER2 positivity, to orient the use of any adjuvant therapies...
June 23, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28650276/highlights-of-the-san-antonio-breast-cancer-symposium-2016
#2
John R Benson, Ismail Jatoi
The 39th annual San Antonio Breast Cancer Symposium (SABCS) was convened in San Antonio, Texas, on 9-13 December 2016. More than 7000 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, locoregional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with Part 1 focusing onmetastatic breast cancer, extended endocrine therapy and the prognostic significance of BRCA1/2 gene mutations...
June 26, 2017: Future Oncology
https://www.readbyqxmd.com/read/28646773/survival-outcomes-of-patients-with-lobular-carcinoma-in-situ-who-underwent-bilateral-mastectomy-or-partial-mastectomy
#3
Ze-Ming Xie, Jian Sun, Zhe-Yu Hu, Yao-Pan Wu, Peng Liu, Jun Tang, Xiang-Sheng Xiao, Wei-Dong Wei, Xi Wang, Xiao-Ming Xie, Ming-Tian Yang
AIM: To compare the survival outcomes between patients treated with bilateral mastectomy and partial mastectomy alone as the initial surgical management for primary lobular carcinoma in situ (LCIS). PATIENTS AND METHODS: Patients with histologically confirmed LCIS underwent partial mastectomy alone or bilateral mastectomy were identified by the SEER*Stat database (version 8.3.2) released in 2016. The primary outcome measure was all-cause mortality and the secondary outcome measure was breast cancer-specific mortality...
June 21, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28645508/merkel-cell-carcinoma-melanoma-metastatic-mimics-of-breast-cancer
#4
REVIEW
Megan L Troxell
Merkel cell carcinoma and melanoma can each occur primarily in breast skin, or metastasize to the breast. The breast is a rare site of metastasis of essentially any and every type of tumor, including carcinomas, sarcomas, and hematolymphoid neoplasms, and 10-30% of breast metastases may represent the initial presentation of disease. Although metastases generally recapitulate histologic features of the primary tumor, they are diagnostically challenging given their rarity and morphologic overlap with breast carcinoma, including special types of breast cancer...
May 31, 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28644994/is-the-systematic-circumferential-tumor-cavity-shaving-a-representative-sample-for-the-remaining-mammary-gland-about-75-cases
#5
H Bouzaiene, A Triki, M Ghalleb, M Chemlali, Z Benzarti, J Ben Hassouna, A Gammoudi, K Rahal
INTRODUCTION: The conservative surgery is more and more indicated for breast cancer. However, we still fear local recurrence which is mostly due to residual tumors?. Several techniques have been used to minimize theses residual tumors; one of them is the systematic circumferential tumor cavity shaving (SCTCS). METHODS: We sampled 75 female patients who had conservative surgery with positive shaved margins in the anatomopathology examination and to whom a complementary treatment with mastectomy have been decided...
June 20, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28641365/ultrasonography-guided-14-gauge-core-biopsy-of-the-breast-results-of-7-years-of-experience
#6
Inha Jung, Min Jung Kim, Hee Jung Moon, Jung Hyun Yoon, Eun-Kyung Kim
Purpose: This study assessed the outcomes of ultrasound (US)-guided core needle biopsies (CNBs) of breast lesions with at least 2 years of follow-up to determine the false-negative rate and to evaluate the diagnostic accuracy of CNB. Methods: We retrospectively analyzed 13,254 consecutive US-guided 14-gauge CNBs for breast lesions. We excluded biopsies if non-malignant biopsy result was not confirmed by surgical excision or US-guided vacuum-assisted biopsy, or fewer than 2 years of follow-up data were available...
May 17, 2017: Ultrasonography
https://www.readbyqxmd.com/read/28640166/missing-documentation-in-breast-cancer-survivors-genitourinary-syndrome-of-menopause
#7
Elise D Cook, Elena I Iglehart, George Baum, Leslie L Schover, Lonzetta L Newman
OBJECTIVE: Breast cancer survivors often take hormonal treatments to prevent the recurrence of breast cancer, particularly aromatase inhibitors that can worsen the symptoms of genitourinary syndrome of menopause (GSM) such as dyspareunia, dysuria, and urinary incontinence, all of which may adversely affect survivors' quality of life. Few breast cancer survivors experiencing GSM receive adequate assessment or treatment. METHODS: In this descriptive study, we reviewed medical records for documented GSM and any treatments administered or referrals for treatment in 800 female patients who visited the Breast Cancer Survivorship Clinic at a comprehensive cancer center between July 1, 2010 and June 30, 2011, either at least 5 years after completion of treatment for invasive breast cancer or at least 6 months after completion of treatment for ductal carcinoma in situ...
June 19, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28637226/epidemiologic-risk-factors-for-in-situ-and-invasive-breast-cancer-among-postmenopausal-women-in-the-nih-aarp-diet-and-health-study
#8
Maeve Mullooly, Zeina G Khodr, Cher M Dallal, Sarah J Nyante, Mark E Sherman, Roni Falk, Linda M Liao, Jeffrey Love, Louise A Brinton, Gretchen L Gierach
Comparing risk factor associations between invasive breast cancers and possible precursors may further understanding of factors related to initiation versus progression. Accordingly, among 190,325 postmenopausal participants in the National Institutes of Health-AARP Diet and Health Study (1995-2011), we compared risk factor associations between incident ductal carcinoma in situ (DCIS: n = 1,453) and invasive ductal carcinomas (n = 7,525) and lobular carcinoma in situ (LCIS: n = 186) and invasive lobular carcinomas (n = 1,191)...
June 16, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28634007/gene-expression-differences-between-ductal-carcinoma-in-situ-with-and-without-progression-to-invasive-breast-cancer
#9
Shusma C Doebar, Anieta M Sieuwerts, Vanja de Weerd, Hans Stoop, John W M Martens, Carolien H M van Deurzen
To understand the molecular alterations driving the progression of ductal carcinoma in situ (DCIS), we compared patients with pure DCIS and patients with DCIS and synchronous invasive breast cancer (IBC). Twelve patients with extensive pure DCIS were included as a representation of indolent lesions with limited invasive capacity. These cases were matched with 12 patients with a limited DCIS component and IBC, representing lesions with a high invasive potential. Matching included age and surrogate DCIS subtypes...
July 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/28628656/ultrasound-guided-cable-free-13-gauge-vacuum-assisted-biopsy-of-non-mass-breast-lesions
#10
Jiwoon Seo, Sun Mi Kim, Mijung Jang, Bo La Yun, Soo Hyun Lee, Eun-Kyu Kim, Eunyoung Kang, So Yeon Park, Woo Kyung Moon, Hye Young Choi, Bohyoung Kim
PURPOSE: To compare the outcomes of ultrasound-guided core biopsy for non-mass breast lesions by the novel 13-gauge cable-free vacuum-assisted biopsy (VAB) and by the conventional 14-gauge semi-automated core needle biopsy (CCNB). MATERIALS AND METHODS: Our institutional review board approved this prospective study, and all patients provided written informed consent. Among 1840 ultrasound-guided percutaneous biopsies performed from August 2013 to December 2014, 145 non-mass breast lesions with suspicious microcalcifications on mammography or corresponding magnetic resonance imaging finding were subjected to 13-gauge VAB or 14-gauge CCNB...
2017: PloS One
https://www.readbyqxmd.com/read/28618103/secretory-pathway-ca-2-atpases-promote-in-vitro-microcalcifications-in-breast-cancer-cells
#11
Donna Dang, Hari Prasad, Rajini Rao
Calcification of the breast is often an outward manifestation of underlying molecular changes that drive carcinogenesis. Up to 50% of all non-palpable breast tumors and 90% of ductal carcinoma in situ present with radiographically dense mineralization in mammographic scans. However, surprisingly little is known about the molecular pathways that lead to microcalcifications in the breast. Here, we report on a rapid and quantitative in vitro assay to monitor microcalcifications in breast cancer cell lines, including MCF7, MDA-MB-231 and Hs578T...
June 15, 2017: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/28612228/pleomorphic-lobular-carcinoma-in-situ-of-the-breast-a-single-institution-experience-with-clinical-follow-up-and-centralized-pathology-review
#12
Marina De Brot, Starr Koslow Mautner, Shirin Muhsen, Victor P Andrade, Anita Mamtani, Melissa Murray, Dilip Giri, Rita A Sakr, Edi Brogi, Tari A King
PURPOSE: The natural history of pleomorphic lobular carcinoma in situ (PLCIS) remains largely unknown. METHODS: A pathology database search (1995-2012) was performed to identify patients diagnosed with an LCIS variant. Patients with synchronous breast cancer and/or no evidence of pleomorphism were excluded. Original slides were re-evaluated by three pathologists to identify a consensus cohort of PLCIS. Borderline lesions with focal atypia were classified as LCIS with pleomorphic features (LCIS-PF)...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28611201/relationship-of-the-breast-ductal-carcinoma-in-situ-immune-microenvironment-with-clinico-pathological-and-genetic-features
#13
Shona Hendry, Jia-Min B Pang, David Byrne, Sunil R Lakhani, Margaret C Cummings, Ian G Campbell, G Bruce Mann, Kylie L Gorringe, Stephen B Fox
The immune microenvironment of breast ductal carcinoma in situ (DCIS) has yet to be fully explored, and the relationship of immune cells to genetic features of DCIS is unknown. <br /><br />Experimental Design: We quantified tumour associated lymphocytes (TILs) and evaluated PD-L1 protein levels by immunohistochemistry in a cohort of pure DCIS (138 and 79 cases respectively), some of which had copy number (n=55) and mutation data (n=20). <br /><br />Results: TILs were identified in the stroma surrounding DCIS (119/138, 86%) and present at a median TIL score of 5% (range 0-90%)...
June 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28611039/chemoprevention-uptake-among-women-with-atypical-hyperplasia-and-lobular-and-ductal-carcinoma-in-situ
#14
Meghna S Trivedi, Austin M Coe, Alejandro Vanegas, Rita Kukafka, Katherine Crew
Women with atypical hyperplasia (AH) and lobular or ductal carcinoma in situ (LCIS/DCIS) are at increased risk of developing invasive breast cancer. Chemoprevention with selective estrogen receptor modulators or aromatase inhibitors can reduce breast cancer risk; however, uptake is estimated to be less than 15% in these populations. We sought to determine which factors are associated with chemoprevention uptake in a population of women with AH, LCIS, and DCIS. Women diagnosed with AH/LCIS/DCIS between 2007 and 2015 without a history of invasive breast cancer were identified (n=1719)...
June 13, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28604763/proline-rich-homeodomain-protein-prh-hhex-is-a-suppressor-of-breast-tumour-growth
#15
R M Kershaw, D Roberts, J Wragg, A M Shaaban, E Humphreys, J Halsall, L Price, R Bicknell, K Gaston, P-S Jayaraman
Breast tumours progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). PRH/HHEX (proline-rich homeodomain/haematopoietically expressed homeobox) is a transcription factor that displays both tumour suppressor and oncogenic activity in different disease contexts; however, the role of PRH in breast cancer is poorly understood. Here we show that nuclear localization of the PRH protein is decreased in DCIS and IBC compared with normal breast. Our previous work has shown that PRH phosphorylation by protein kinase CK2 prevents PRH from binding to DNA and regulating the transcription of multiple genes encoding growth factors and growth factor receptors...
June 12, 2017: Oncogenesis
https://www.readbyqxmd.com/read/28602450/pain-sensory-disturbances-and-psychological-distress-among-danish-women-treated-for-ductal-carcinoma-in-situ-an-exploratory-study
#16
Birgitte Goldschmidt Mertz, Helle M Duriaud, Niels Kroman, Kenneth G Andersen
Ductal carcinoma in situ is a noninvasive precancer condition. The treatment resembles the treatment of invasive breast cancer. The aim of this exploratory study was to gain knowledge on the level of postoperative pain, sensory disturbances, and distress among a small group of Danish women with ductal carcinoma in situ who had sentinel lymph node biopsy in order to plan a population study. A subgroup of patients with ductal carcinoma in situ (n = 20) was compared to patients with invasive breast cancer (n = 455) at time of diagnosis and after 12 months...
June 8, 2017: Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses
https://www.readbyqxmd.com/read/28595965/low-expression-of-estrogen-receptor-%C3%AE-and-progesterone-receptor-in-human-breast-cancer-tissues-is-associated-with-high-grade-human-cytomegalovirus-protein-expression
#17
Afsar Rahbar, Joel Touma, Helena Costa, Belghis Davoudi, Ida Rashid Bukholm, Torill Sauer, Katja Vetvik, Jürgen Geisler, Cecilia Söderberg-Naucler
BACKGROUND: The underlying mechanisms for breast cancer (BC) are largely unknown. We investigated possible correlations between the expression levels of human cytomegalovirus (HCMV) proteins and established histopathological markers of BC, including expression of estrogen receptor (ER)-α, the progesterone receptor (PgR), and HER2. MATERIALS AND METHODS: We retrospectively examined paraffin-embedded biopsy specimens of BC (n = 62), ductal carcinoma in situ (n = 19), and adjacent normal breast tissue (n = 42) for HCMV immediate-early protein (IE), HCMV late antigen, HCMV DNA and RNA, and investigated possible correlations between them and expression of ER-α, PgR, and HER2...
May 11, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28595742/-internal-quality-control-on-her2-status-determination-in-breast-cancers-experience-of-a-cancer-center
#18
Carine Ngo, Marick Laé, Julia Ratour, Frédérique Hamel, Corinne Taris, Martial Caly, Annie Le Cunff, Fabien Reyal, Youlia Kirova, Jean-Yves Pierga, Anne Vincent-Salomon
INTRODUCTION: The implementation of an internal quality control is mandatory to guarantee the accuracy of HER2 status in invasive breast cancers. OBJECTIVES: To evaluate the impact of our quality control assurance on HER2 status results in invasive breast carcinomas from 2008 to 2014. METHODS: HER2 status was determined by immunohistochemistry as the first-line indication, completed by fluorescence in situ hybridization (FISH) for scores 2+ by immunohistochemistry...
June 5, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28589368/reassessing-risk-models-for-atypical-hyperplasia-age-may-not-matter
#19
REVIEW
Emanuele Mazzola, Suzanne B Coopey, Molly Griffin, Fernanda Polubriaginof, Julliette M Buckley, Giovanni Parmigiani, Judy E Garber, Barbara L Smith, Michele A Gadd, Michelle C Specht, Anthony Guidi, Kevin S Hughes
PURPOSE: The aim of this study was to investigate the influence of age at diagnosis of atypical hyperplasia ("atypia", ductal [ADH], lobular [ALH], or severe ADH) on the risk of developing subsequent invasive breast cancer or ductal carcinoma in situ (DCIS). METHODS: Using standard survival analysis methods, we retrospectively analyzed 1353 women not treated with chemoprevention among a cohort of 2370 women diagnosed with atypical hyperplasia to determine the risk relationship between age at diagnosis and subsequent breast cancer...
June 6, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28586960/preliminary-results-of-a-phase-1-dose-escalation-trial-for-early-stage-breast-cancer-using-5-fraction-stereotactic-body-radiation-therapy-for-partial-breast-irradiation
#20
Asal Rahimi, Kimberly Thomas, Ann Spangler, Roshni Rao, Marilyn Leitch, Rachel Wooldridge, Aeisha Rivers, Stephen Seiler, Kevin Albuquerque, Stella Stevenson, Sally Goudreau, Dan Garwood, Barbara Haley, David Euhus, John Heinzerling, Chuxiong Ding, Ang Gao, Chul Ahn, Robert Timmerman
PURPOSE: To evaluate the tolerability of a dose-escalated 5-fraction stereotactic body radiation therapy for partial-breast irradiation (S-PBI) in treating early-stage breast cancer after partial mastectomy; the primary objective was to escalate dose utilizing a robotic stereotactic radiation system treating the lumpectomy cavity without exceeding the maximum tolerated dose. METHODS AND MATERIALS: Eligible patients included those with ductal carcinoma in situ or invasive nonlobular epithelial histologies and stage 0, I, or II, with tumor size <3 cm...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
43940
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"